Boehringer Ingelheim picked up FDA approval for a next-generation COPD treatment, looking to contend for a share of the fast-crowding market for combination therapies.
Boehringer Ingelheim has made a quick decision about Pharmaxis' non-alcoholic steatohepatitis (NASH) drug, striking a $250 million deal to buy the Phase I asset just two months after inking an option to acquire the program.
Boehringer Ingelheim has exercised an option to buy PXS4728A from Australia-based Pharmaxis and develop it for the treatment of the liver-related condition NASH with the candidate also showing potential in chronic obstructive pulmonary disease.
Slumping sales for cardiovascular drugs isn't exactly a new phenomenon for Big Pharma, with some of the industry's top drugmakers suffering from recent patent expirations. But a new report shows which CV franchises have been hurt the most.
Large pharma companies are posting 530% more tweets a week than in 2013, a study by Ogilvy Healthworld found. The healthcare communications group tracked the social media activity of 14 large pharma companies for one week per month over three months.
Boehringer Ingelheim already had the FDA's "breakthrough" designation on idarucizumab, an antidote to its blockbuster anticoagulant Pradaxa. Now, the reversal agent has stepped on the agency's fast track, which cuts review time by four months.
Eli Lilly and Boehringer Ingelheim secured a recommendation from European regulators for their combination diabetes treatment, making for a likely continental approval in the coming months.
Newcomers showed off at this year's American Academy of Dermatology meeting, with more than one touting Stelara-beating data--and prepping the market for an all-out psoriasis war.
Nearly 250 workers at a closed Boehringer Ingelheim API facility in Virginia that had been told they might be able to hold on to their jobs have had their hopes dashed. The Chinese company that agreed to buy and expand the facility has decided to leave it closed until business improves.
Psoriasis has attracted a big pack of rival drug giants anxious to be in the lead with a new wave of better, targeted therapies for legions of patients. But a team of investigators at Rockefeller University say they just scored early-stage data on a new drug from Boehringer Ingelheim that promises to offer a potential cure with a more durable therapy.